Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ophthalmology
Biotech
Qlaris sees double as drug reduces eye pressure in ph. 2 trials
Qlaris Bio hit the primary endpoints in two mid-stage trials that both spanned primary open-angle glaucoma and ocular hypertension.
James Waldron
Feb 5, 2025 9:53am
Aviceda raises $207M for geographic atrophy drug's ph. 3 journey
Jan 7, 2025 9:38am
Oculis peptidomimetic helps protect eyes from nerve inflammation
Jan 6, 2025 5:27am
Aurion's regenerative med improves vision in phase 1/2 trial
Dec 18, 2024 7:00am
2 eye disease biotechs merge, set sights on FDA approval
Dec 12, 2024 11:05am
China-based biotech plans ph. 3 after seeing midstage eye data
Oct 22, 2024 10:37am
